Wells et al developed a score for the myelodysplastic syndrome (MDS) based on flow cytometric findings. The final score is the sum of the scores for myeloid and monocytoid abnormalities. The authors are from the Hematologics, Inc, Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle.
Patient selection: myelodysplasia with percent blasts <= 30%
Parameters:
(1) subscore for myeloid abnormalities (
(2) subscore for monocytoid abnormalities
final score =
= (subscore for myeloid abnormalities) + (subscore for monocytoid abnormalities)
Interpretation:
• minimum score: 0
• maximums score: 11
• The higher the score the more likely that the patient has myelodysplasia,
• A score >= 3 has a specificity of 100% but sensitivity of 55%.
• The best Youden score (and best percent correctly classified) was associated with a score >= 2 (sensitivity 70% and specificity 93%).
Final Score
Abnormality
0 or 1
none or mild
2 or 3
moderate
4 or more
severe
To read more or access our algorithms and calculators, please log in or register.
